Glulisine Pre- and Postmeal

• Status: Completed
• Trial end date: 2002-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate in type 1 diabetic patients the glucodynamic response to HMR1964 insulin and RHI (HOE31HPR100) injected subcutaneously before and after a standard meal

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Insulin; Insulin glulisine; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 1 diabetes mellitus

Exclusion Criteria: